SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

PSMA and Beyond PSMA-targeted prostate biopsy, MRI-guided biopsy, PIRADS 2 lesion, 68Ga-PSMA-11, PSMA guided fusion biopsy, PIRADS delineation, SUVmax and PRIMARY score.

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

Andrea Miyahira speaks with Salomon Tendler about his work targeting neuroendocrine prostate cancer (NEPC), an aggressive castration-resistant form affecting 15-20% of advanced prostate cancer ...

UroToday's exclusive Video Lecture content covering Advanced Prostate Cancer.

Clear explanation of what a "Foley" or indwelling catheter is, the 2 types of insertions, their use cases, and the risk of CAUTI if catheterization isn't properly managed.

ASCO GU 2024, CheckMate 214 trial, nivolumab, ipilimumab, nivolumab plus ipilimumab, renal cell carcinoma (RCC), checkpoint inhibitor combination therapy.

ASCO 2025 PSMA–positive biochemically recurrent prostate cancer, metastatic castration sensitive prostate cancer (mCSPC), mCSPC trials.

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein which functions as a zinc metalloenzyme and is found on prostatic epithelium. In normal prostate tissue, PSMA ...